The corneal endothelium showed a beaten bronze appearance without corneal edema (Figure 1b). The left fundus showed significant retinal venous tortuosity with an otherwise normal retina and a ...

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

Important insights into the mechanisms behind Fuchs endothelial corneal dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers.

Alcon said that its majority stake means that Aurion will have "broader R&D, regulatory, medical ophthalmic, and commercial ...

Fast-tracked cross-appeals in Delaware by Alcon Research LLC and Aurion Biotech Inc. have been closed, now that Alcon has bought a majority stake in the company that’s developing a potentially ...

Thanks to the donation of the infant’s corneas, a successful cornea transplantation was performed in the 48-year-old woman at ...

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company ...

Iridocorneal endothelial (ICE) syndrome is a rare, irreversibly blinding ocular disorder with an unknown etiology. Lack of targeted effective drugs, inadequate disease prognosis, and high relapse ...